These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 26496897)

  • 1. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
    Weng WH; Leung WH; Pang YJ; Hsu HH
    Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
    Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
    Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA Expression in
    Lundberg IV; Wikberg ML; Ljuslinder I; Li X; Myte R; Zingmark C; Löfgren-Burström A; Edin S; Palmqvist R
    Anticancer Res; 2018 Feb; 38(2):677-683. PubMed ID: 29374690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.
    Igarashi H; Kurihara H; Mitsuhashi K; Ito M; Okuda H; Kanno S; Naito T; Yoshii S; Takahashi H; Kusumi T; Hasegawa T; Sukawa Y; Adachi Y; Okita K; Hirata K; Imamura Y; Baba Y; Imai K; Suzuki H; Yamamoto H; Nosho K; Shinomura Y
    Ann Surg Oncol; 2015 Aug; 22(8):2640-8. PubMed ID: 25472647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers.
    Choi YW; Song YS; Lee H; Yi K; Kim YB; Suh KW; Lee D
    Medicine (Baltimore); 2016 Apr; 95(15):e3321. PubMed ID: 27082577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab promotes SN38 sensitivity via suppression of heat shock protein 27 in colorectal cancer cells with wild-type RAS.
    Ishida T; Ishii Y; Tsuruta M; Okabayashi K; Akimoto S; Koishikawa K; Hasegawa H; Kitagawa Y
    Oncol Rep; 2017 Aug; 38(2):926-932. PubMed ID: 28656305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer.
    Hiraide S; Takahashi M; Yoshida Y; Yamada H; Komine K; Ishioka C
    Cancer Sci; 2021 Sep; 112(9):3856-3870. PubMed ID: 34288281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
    Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
    J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
    Song K; Lu H; Jin L; Wang K; Guo W; Zheng H; Li K; He C; You T; Fu Y; Yang J; Zhao W; Guo Z
    FEBS J; 2020 Dec; 287(23):5236-5248. PubMed ID: 32216031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
    Song Q; Sun X; Guo H; Yu Q
    Oncotarget; 2017 Jan; 8(3):5003-5015. PubMed ID: 28002807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
    Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.
    Mosakhani N; Lahti L; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S; Sarhadi VK
    Cancer Genet; 2012 Nov; 205(11):545-51. PubMed ID: 23098991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway.
    Nosho K; Igarashi H; Nojima M; Ito M; Maruyama R; Yoshii S; Naito T; Sukawa Y; Mikami M; Sumioka W; Yamamoto E; Kurokawa S; Adachi Y; Takahashi H; Okuda H; Kusumi T; Hosokawa M; Fujita M; Hasegawa T; Okita K; Hirata K; Suzuki H; Yamamoto H; Shinomura Y
    Carcinogenesis; 2014 Apr; 35(4):776-83. PubMed ID: 24242331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.